Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pertuzumab

- PMLiVE

NICE backs Celgene’s Revlimid in bone marrow disorder

Recommends that drug can be used on NHS to treat myelodysplastic syndromes

- PMLiVE

Chugai soars on Roche buyout rumours

Reports circulating that Swiss company is poised to make $10bn offer

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

- PMLiVE

Avastin gets US green light for late-stage cervical cancer

Fifth oncology indication for Roche’s medicine

- PMLiVE

UK pharmacies can play bigger public health role

Report says pharmacies should extend range of services for communities

National Institute for Health and Care Excellence NICE logo

Public advises NICE on value of care

Citizens Council publishes report on the way health and social care resources are allocated in the UK

- PMLiVE

Roche blasts UK’s ‘broken’ HTA system as Kadcyla rejected

But NICE says it is 'very disappointed' with the company's pricing policy

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

Roche Basel Switzerland

Roche pays $450m for ‘gene-silencing’ firm Santaris Pharma

Deal marks major return to the RNAi field it exited four years ago

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

Roche - Basel

Roche wins European approval for new leukaemia drug

Gazyvaro now available for use in treatment of blood cancer in the EU

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links